A
Adam C. Yopp
Researcher at University of Texas Southwestern Medical Center
Publications - 229
Citations - 9266
Adam C. Yopp is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 39, co-authored 193 publications receiving 6427 citations. Previous affiliations of Adam C. Yopp include Memorial Sloan Kettering Cancer Center & Maimonides Medical Center.
Papers
More filters
Journal ArticleDOI
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Agnieszka K. Witkiewicz,Elizabeth A. McMillan,Uthra Balaji,Guem Hee Baek,Wan Chi Lin,John C. Mansour,Mehri Mollaee,Kay Uwe Wagner,Prasad Koduru,Adam C. Yopp,Michael A. Choti,Charles J. Yeo,Peter McCue,Michael A. White,Erik S. Knudsen +14 more
TL;DR: It is shown that environmental stress and alterations in DNA repair genes associate with distinct mutation spectra, and multiple novel mutated genes in PDA are identified, with select genes harbouring prognostic significance.
Journal ArticleDOI
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.
Itaru Endo,Mithat Gonen,Adam C. Yopp,Kimberly Moore Dalal,Qin Zhou,David S. Klimstra,Michael I. D’Angelica,Ronald P. DeMatteo,Yuman Fong,Lawrence H. Schwartz,Nancy E. Kemeny,Eileen M. O'Reilly,Ghassan K. Abou-Alfa,Hiroshi Shimada,Leslie H. Blumgart,William R. Jarnagin +15 more
TL;DR: At Memorial Sloan-Kettering Cancer Center, intrahepatic cholangiocarcinoma incidence has increased dramatically in the last 16 years and the recent increase in survival seems largely because of improved nonoperative therapy for unresectable disease.
Journal ArticleDOI
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.
Kristina Tzartzeva,Joseph Obi,Nicole E. Rich,Neehar D. Parikh,Jorge A. Marrero,Adam C. Yopp,Akbar K. Waljee,Amit G. Singal +7 more
TL;DR: It is found ultrasound alone has a low sensitivity to detect early stage HCC in patients with cirrhosis and addition of AFP to ultrasound significantly increases sensitivity of early HCC detection in clinical practice.
Journal ArticleDOI
Hepatobiliary cancers, Version 2.2021
Al B. Benson,Michael I. D’Angelica,Daniel E. Abbott,Daniel A. Anaya,Robert A. Anders,Chandrakanth Are,Melinda Bachini,Mitesh J. Borad,Daniel B. Brown,Adam M. Burgoyne,Prabhleen Chahal,Daniel T. Chang,Jordan M. Cloyd,Anne M. Covey,Evan S. Glazer,Lipika Goyal,William G. Hawkins,Renuka Iyer,Rojymon Jacob,R. Kate Kelley,Robin D. Kim,Matthew H. Levine,Manisha Palta,James O. Park,Steven S. Raman,Sanjay S. Reddy,Vaibhav Sahai,Tracey E. Schefter,Gagandeep Singh,Stacey Stein,Jean Nicolas Vauthey,Alan P. Venook,Adam C. Yopp,Nicole R. McMillian,Cindy Hochstetler,Susan Darlow +35 more
TL;DR: The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts as discussed by the authors.
Journal ArticleDOI
Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Ali A. Mokdad,Rebecca M. Minter,Hong Zhu,Mathew M. Augustine,Matthew R. Porembka,Sam C. Wang,Adam C. Yopp,John C. Mansour,Michael A. Choti,Patricio M. Polanco +9 more
TL;DR: Findings support the use of NAT, particularly as a patient selection tool, in the management of resectable pancreatic adenocarcinoma, as well as a subset of UR patients who received adjuvant therapy, which has a significant survival benefit compared with UR in early-stage, resected pancreatic head adenOCarcinomas.